

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

Dated April 26, 2017

Commission File Number 001-36421

---

**AURINIA PHARMACEUTICALS INC.**

(Exact name of Registrant as specified in its charter)

---

N/A

(Translation of Registrant's Name)

#1203-4464 Markham Street  
Victoria, British Columbia  
V8Z7X8

(250) 708-4272

(Address and telephone number of registrant's principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

This Form 6-K is hereby filed and incorporated by reference into the Registrant's Registration Statement on Form F-10 (File No. 333-206994).

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: April 26, 2017.

### **Aurinia Pharmaceuticals Inc.**

By: /s/ Celia Economides

\_\_\_\_\_  
Name: Celia Economides

Title: Head of IR & Communications

## EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
99.1	News Release – <b>Aurinia to Present at Bloom Burton &amp; Co. Healthcare Conference</b>

---

Exhibit 99.1 included with this report on Form 6-K is hereby incorporated by reference as an exhibit to the Registrant's Registration Statement on Form F-10 (File No. 333-206994), as amended or supplemented.

## Aurinia to Present at Bloom Burton & Co. Healthcare Conference

VICTORIA, British Columbia--(BUSINESS WIRE)--April 26, 2017--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that its Chief Executive Officer, Richard M. Glickman, will present at the Bloom Burton & Co. Healthcare Conference in Toronto, Ontario on May 2, 2017 at 11:30am ET. A webcast will be available and can be accessed via the investor section of the Aurinia website, [www.auriniapharma.com](http://www.auriniapharma.com). A replay will also be archived on the site following the event.

### *About Aurinia*

Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), an inflammation of the kidney caused by Systemic Lupus Erythematosus (SLE) and represents a serious progression of SLE. The company is headquartered in Victoria, BC and focuses its development efforts globally. [www.auriniapharma.com](http://www.auriniapharma.com).

### *We Seek Safe Harbor.*

#### CONTACT:

**Aurinia Pharmaceuticals Inc.**

#### **Investor & Media Contact:**

Celia Economides

Head of IR & Communications

[ceconomides@auriniapharma.com](mailto:ceconomides@auriniapharma.com)